The global value of the Cancer Diagnostic Market is anticipated to increase from USD 197.7 billion in 2025 to USD 345.57 billion by 2033, at a CAGR of 7.23% during 2025-2033. The increasing incidence of cancer, advancements in diagnostic technologies, and growing awareness about the importance of early diagnosis are some major factors that will lead to the expansion of the cancer diagnostics field. Increased demand for personalized medicine and improved imaging services further creates new avenues in the market. Cancer diagnostics will continue to emerge as an important sector in healthcare, thus enabling the early detection of various types of cancers and improving patient outcomes.
Cancer diagnostics are the methods and techniques of identifying cancer within an individual. Such diagnosis often involves a number of tests, which include imaging studies such as X-rays, CT scans, or MRIs; biopsies; and blood tests that can identify certain biomarkers associated with cancer. The goal is to diagnose cancer as early as possible to improve treatment outcomes and survival rates.
Cancer diagnostics have recently gained high popularity globally due to increased incidences of the disease and awareness about it. With heightened awareness of health issues and the benefits of early disease diagnosis, there has been an upward surge in demand for more advanced diagnostic tools. Technological advancements in genomics, liquid biopsies, and artificial intelligence have greatly enhanced the accuracy and efficiency of cancer diagnostics, thus making them more accessible.
Public health campaigns and initiatives on regular screenings and creating awareness have also contributed to this growing emphasis on early diagnosis. This trend not only improves the care of individual patients but also aids in the strategic allocation of healthcare resources globally, with nations seeking to fight cancer effectively.
Headquarters: United States of America
Illumina Inc. develops and commercializes genomic sequencing and array-based technologies for genetic analysis in consumer genomics, translational genomics, cancer research, and molecular diagnostics. A wide range of product offerings includes sequencing systems and consumables, microarray kits and sequencing kits, molecular biology reagents, and corresponding consumables. Illumina also provides services regarding whole-genome sequencing, microarray analysis, instrument consulting, maintenance, and training. The typical customers are pharmaceutical and biotechnology corporations, universities and research institutions, clinical research groups, and genomics research organizations. Illumina distributes its products through a mix of direct marketing and distribution networks in various geographies such as the Americas, Europe, Asia-Pacific, Middle East, and Africa.
Founded: 1888
Abbott Laboratories develops, manufactures, and sells a wide range of medical and health care products, including nutritionals and diagnostics. The company develops products mainly for gastroenterology and women's health, while its other key areas of operations include cardiovascular and metabolic health, pain management, and central nervous system disorders. Abbott will also manufacture respiratory drugs and vaccines, biosimilars, core laboratory systems, and transfusion medicine technologies. The product portfolio will further comprise point-of-care systems, rapid diagnostic lateral flow tests, informatics and automation solutions, nutritional products, and rhythm management, electrophysiology, and heart failure-related devices. Abbott deals with a wide range of vascular and structural heart needs and neuromodulation therapies. Its products are sold to wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and independent retailers in North America, Latin America, the Middle East, Europe, Asia-Pacific, and Africa.
Headquarters: United States of America
Thermo Fisher Scientific Inc. has emerged as one of the global leaders in providing analytical instruments, life sciences solutions, specialty diagnostics, and laboratory services. Its product portfolio includes laboratory equipment, instruments, clinical diagnostic products, chromatography and mass spectrometry systems, chemicals, cell culture products, and molecular biology products. Thermo Fisher markets its products to pharmaceutical and biotechnology firms, hospitals, clinical laboratories, academic research institutions, and government agencies. The major brands of the company are Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. The company sells its products through a worldwide direct sales and customer service professional network, e-commerce websites, and third-party distributors.
Headquarters: Switzerland
F. Hoffmann-La 'Roche Ltd. is a leading global biotechnology company in in-vitro diagnostics, pioneering innovative solutions in major disease areas. The company develops and supplies medicines in cancer, autoimmune diseases, central nervous system disorders, eye diseases, infectious diseases, and respiratory diseases. Other solutions also include in-vitro diagnosis, tissue-based cancer diagnosis, and diabetes care. The company undertakes active research and development activities with a strategic aim of finding new ways of preventing, diagnosing, and treating several diseases. Roche provides its entire range of products and services to hospitals, doctors and healthcare professionals, laboratories for commercial purposes, researchers, and pharmacists.
Cancer diagnostics are the methods and techniques of identifying cancer within an individual. Such diagnosis often involves a number of tests, which include imaging studies such as X-rays, CT scans, or MRIs; biopsies; and blood tests that can identify certain biomarkers associated with cancer. The goal is to diagnose cancer as early as possible to improve treatment outcomes and survival rates.
Cancer diagnostics have recently gained high popularity globally due to increased incidences of the disease and awareness about it. With heightened awareness of health issues and the benefits of early disease diagnosis, there has been an upward surge in demand for more advanced diagnostic tools. Technological advancements in genomics, liquid biopsies, and artificial intelligence have greatly enhanced the accuracy and efficiency of cancer diagnostics, thus making them more accessible.
Public health campaigns and initiatives on regular screenings and creating awareness have also contributed to this growing emphasis on early diagnosis. This trend not only improves the care of individual patients but also aids in the strategic allocation of healthcare resources globally, with nations seeking to fight cancer effectively.
Top 5 Companies in the Cancer Diagnostics Market by 2033
Illumina, Inc.
Founding: 1998Headquarters: United States of America
Illumina Inc. develops and commercializes genomic sequencing and array-based technologies for genetic analysis in consumer genomics, translational genomics, cancer research, and molecular diagnostics. A wide range of product offerings includes sequencing systems and consumables, microarray kits and sequencing kits, molecular biology reagents, and corresponding consumables. Illumina also provides services regarding whole-genome sequencing, microarray analysis, instrument consulting, maintenance, and training. The typical customers are pharmaceutical and biotechnology corporations, universities and research institutions, clinical research groups, and genomics research organizations. Illumina distributes its products through a mix of direct marketing and distribution networks in various geographies such as the Americas, Europe, Asia-Pacific, Middle East, and Africa.
Abbott Laboratories
Headquarters: United States of AmericaFounded: 1888
Abbott Laboratories develops, manufactures, and sells a wide range of medical and health care products, including nutritionals and diagnostics. The company develops products mainly for gastroenterology and women's health, while its other key areas of operations include cardiovascular and metabolic health, pain management, and central nervous system disorders. Abbott will also manufacture respiratory drugs and vaccines, biosimilars, core laboratory systems, and transfusion medicine technologies. The product portfolio will further comprise point-of-care systems, rapid diagnostic lateral flow tests, informatics and automation solutions, nutritional products, and rhythm management, electrophysiology, and heart failure-related devices. Abbott deals with a wide range of vascular and structural heart needs and neuromodulation therapies. Its products are sold to wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and independent retailers in North America, Latin America, the Middle East, Europe, Asia-Pacific, and Africa.
Thermo Fisher Scientific Inc.
Establishment: 2006Headquarters: United States of America
Thermo Fisher Scientific Inc. has emerged as one of the global leaders in providing analytical instruments, life sciences solutions, specialty diagnostics, and laboratory services. Its product portfolio includes laboratory equipment, instruments, clinical diagnostic products, chromatography and mass spectrometry systems, chemicals, cell culture products, and molecular biology products. Thermo Fisher markets its products to pharmaceutical and biotechnology firms, hospitals, clinical laboratories, academic research institutions, and government agencies. The major brands of the company are Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. The company sells its products through a worldwide direct sales and customer service professional network, e-commerce websites, and third-party distributors.
QIAGEN N.V.
Founding: 1984Head Office: Netherlands
F. Hoffmann-La Roche Ltd.
Establishment: 1896Headquarters: Switzerland
F. Hoffmann-La 'Roche Ltd. is a leading global biotechnology company in in-vitro diagnostics, pioneering innovative solutions in major disease areas. The company develops and supplies medicines in cancer, autoimmune diseases, central nervous system disorders, eye diseases, infectious diseases, and respiratory diseases. Other solutions also include in-vitro diagnosis, tissue-based cancer diagnosis, and diabetes care. The company undertakes active research and development activities with a strategic aim of finding new ways of preventing, diagnosing, and treating several diseases. Roche provides its entire range of products and services to hospitals, doctors and healthcare professionals, laboratories for commercial purposes, researchers, and pharmacists.
Product Launches in the Cancer Diagnostics Market
Pfizer, Inc.
Sept. 2025 - Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for breast cancer and other conditions, announced a new clinical trial collaboration and supply agreement with Pfizer Inc. regarding metastatic breast cancer. Both companies will conduct a Phase 1b/2 study evaluating the safety and compatibility of palazestrant combined with atirmociclib, Pfizer's investigational, highly selective CDK4 inhibitor, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer.Koninklijke Philips N.V.
Sep 2025, At the 2025 Annual Meeting of the American Society for Radiation Oncology, Royal Philips, the global leader in health technology, is introducing groundbreaking innovations in radiation oncology, including the Philips Rembra RT and Philips Areta RT CT platforms, alongside the latest helium-free BlueSeal RT 1.5T MR system. These technologies are designed to support radiation oncology teams in delivering highly accurate, efficient, and more patient-centered care. Innovations such as the new NanoPanel Precise XD detector, designed for artificial intelligence, and the AI-based Smartspeed Precise represent a significant step forward in addressing the increasing complexities of radiation therapy planning.SWOT Analysis of Company
bioMérieux
The main strength of bioMérieux in the cancer diagnostics market is being able to offer a deep level of competence in IVD and molecular biology, thus allowing the company to develop highly specific and sensitive tools for the detection of cancers. With decades of experience in clinical diagnostics, bioMérieux has established a strong technological foundation in molecular assays, immunoassays, and biomarker detection that are crucial for the early diagnosis of cancer and patient monitoring. The company's global R&D network and partnerships with leading oncology research institutions inspire continuous innovation in diagnostic technologies, including liquid biopsy and companion diagnostics. Its products ensure accuracy, reproducibility, and adherence to strict regulatory standards and are recognized around the world. Additionally, the broad base of hospital and laboratory partnerships that bioMérieux enjoys ensures effective market reach and clinical integration. Combining scientific excellence, data-driven innovation, and clinical reliability positions bioMérieux for further improvements in personalized oncology care and strengthening its leadership within the global cancer diagnostics market.Siemens Healthineers AG
The main strength of Siemens Healthineers AG in the market for cancer diagnostics is its unparalleled expertise in the provision of advanced medical imaging and integrated diagnostic solutions. The portfolio includes state-of-the-art technologies in MRI, CT, PET-CT, and molecular imaging systems that enable the detection of tumors with high diagnostic accuracy, staging, and treatment monitoring. Thus, Siemens Healthineers combines imaging, laboratory diagnostics, and digital health for a holistic, data-driven approach to oncology diagnostics. It is also investing heavily in AI and automation, further improving diagnostic precision, workflow efficiency, and personalizing treatment plans. Siemens Healthineers boasts a global reach and has long-term relationships with health institutions to ensure broad access to innovative cancer diagnostic technologies. Besides, a highlight on collaboration in research and precision medicine further cements its competitive advantage. By merging technology, clinical insight, and digital innovation, Siemens Healthineers leads in transforming cancer diagnostics into more precise, connected, and patient-centered healthcare solutions.Recent Development in the Cancer Diagnostics Market
Danaher Corporation
May 2025 Danaher Corporation has collaborated with AstraZeneca to develop new diagnostic tools that will enhance the selection of patients for precision medicine treatments. According to Danaher's news release, the collaboration will center on using digital pathology products and AI algorithms from Leica Biosystems at the new Danaher Centers for Enabling Precision Medicine to help clinicians recognize those patients most likely to benefit from targeted therapies.Becton, Dickinson and Company
July 2024, BD and Quest Diagnostics announced a global collaboration to develop, manufacture and commercialize companion diagnostics leveraging flow cytometry technology to aid in determining optimal treatments for cancer and other diseases. The partnership will offer the pharmaceutical industry with a comprehensive solution ranging from exploratory panel development through FDA-approved diagnostic kit offerings.Sustainability Goal
Agilent Technologies, Inc.
Agilent Technologies, Inc. endeavors through its sustainability goals to harness the power of scientific innovation in service of a healthier planet, responsible operations, and inclusive growth. The company pledges to reach net-zero greenhouse gas emissions no later than 2050, and its strategy will be aligned with global goals on climate. Agilent implements sustainability within its value chain through energy use reduction, waste minimization, designing products for recyclability, and green manufacturing. Laboratories and facilities are optimized for energy efficiency, while its sourcing programs ensure that suppliers are ethical and environmentally responsible. Beyond its environmental programs, social sustainability at Agilent encompasses employee well-being, diversity, and community outreach. It further advances science through various educational programs and collaborative partnerships to improve environmental research and public health. Agilent combines innovation, transparency, and environmental care in the development of sustainable scientific solutions that enable customers to make breakthroughs possible while protecting the planet for future generations.Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. aims to integrate environmental stewardship, social responsibility, and ethical governance into its mission to advance scientific discovery and healthcare innovation. It is committed to decreasing its environmental footprint by improving energy efficiency, minimizing waste, and using sustainable materials in its products and packaging. Bio-Rad is pursuing a path to carbon neutrality through the use of renewable energy and sustainable manufacturing. It is focusing on responsible management of water and reducing waste within its laboratories and production facilities. It encourages diversity, inclusiveness, and community outreach, while offering a safe and supportive workplace culture. Bio-Rad runs its business highly ethically in research, ensuring the safety of its products, and maintaining supply chain transparency. By aligning its business practices with the United Nations SDGs, Bio-Rad aims to deliver long-term value: enabling scientific progress yet preserving resources for future generations.Market Segmentation
Cancer Diagnostics Market
- Historical Trends
- Forecast Analysis
Market Share Analysis - Cancer Diagnostics Market
llumina, Inc.
Overview
- Company History and Mission
- Business Model and Operations
- Workforce
Key Persons
- Executive Leadership
- Operational Management
- Division Leaders
- Board Composition
Recent Development & Strategies
- Mergers & Acquisitions
- Partnerships
- Investments
Sustainability Analysis
- Renewable Energy Adoption
- Energy-Efficient Infrastructure
- Use of Sustainable Packaging Materials
- Water Usage and Conservation Strategies
- Waste Management and Circular Economy Initiatives
Product Analysis
- Product Profile
- Quality Standards
- Product Pipeline
- Product Benchmarking
Strategic Assessment: SWOT Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
Revenue Analysis
The above information will be available for all the following companies:
- Illumina, Inc.
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- QIAGEN N.V.
- Roche Holding AG.
- Pfizer, Inc.
- Koninklijke Philips N.V.
- bioMérieux
- Siemens Healthineers AG
- Danaher Corporation (Cepheid)
- Becton, Dickinson and Company (BD)
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Hologic, Inc.
- Myriad Genetics, Inc.
- PerkinElmer, Inc. (Revvity)
- GE HealthCare Technologies, Inc.
- Sysmex Corporation
- Exact Sciences Corporation
- Guardant Health, Inc.
Table of Contents
1. Cancer Diagnostics Market
3. Llumina
The above information will be available for all the following companies:
Companies Mentioned
- Illumina, Inc.
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- QIAGEN N.V.
- Roche Holding AG.
- Pfizer, Inc.
- Koninklijke Philips N.V.
- bioMérieux
- Siemens Healthineers AG
- Danaher Corporation (Cepheid)
- Becton, Dickinson and Company (BD)
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Hologic, Inc.
- Myriad Genetics, Inc.
- PerkinElmer, Inc. (Revvity)
- GE HealthCare Technologies, Inc.
- Sysmex Corporation
- Exact Sciences Corporation
- Guardant Health, Inc.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 197.7 Billion |
| Forecasted Market Value ( USD | $ 345.57 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
